Stock Market & Financial Investment News

News Breaks December 19, 2012 13:32 EDT AMGN Amgen finalizes $762M agreement to settle federal investigations Amgen announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related to previously disclosed investigations. Amgen will pay approximately $612M to resolve its civil liability related to certain promotional practices related to the drugs Aranesp, EPOGEN, NEUPOGEN, Neulasta, Enbrel and Sensipar as alleged in the unsealed qui tam complaints and $150M to resolve its criminal liability relating to the marketing of Aranesp, and the $762M agreement is covered by a 3Q11 charge. The company also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. As part of the agreement, Amgen has pleaded guilty to a single misdemeanor count of misbranding Aranesp by promoting it in a way that was different from the dosages in the label. The plea was entered yesterday in the U.S. District Court for the Eastern District of New York and was accepted today by the same court. News For AMGN From The Last 14 Days Check below for free stories on AMGN the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 19:07 EDT AMGN On The Fly: After Hours Movers Subscribe for More Information 17:25 EDT AMGN Amgen reports 7.58% stake in Cytokinetics Subscribe for More Information June 16, 2013 11:44 EDT AMGN Amgen still looks attractive, Barron's says Subscribe for More Information June 13, 2013 11:06 EDT AMGN FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information 11:04 EDT AMGN FDA approves Xgeva to treat giant cell tumor of the bone Subscribe for More Information 07:32 EDT AMGN European League Against Rheumatism to host annual meeting Subscribe for More Information June 12, 2013 09:13 EDT AMGN Amgen, AstraZeneca to advance brodalumab into Phase 3 studies Subscribe for More Information 09:04 EDT AMGN Amgen announces positive top-line results of Phase 3 trebananib Subscribe for More Information 07:39 EDT AMGN Amgen, Cytokinetics announce expansion of license for omecamtiv mecarbil Subscribe for More Information June 11, 2013 07:31 EDT AMGN Goldman to host a conference Subscribe for More Information June 10, 2013 07:40 EDT AMGN Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information 07:20 EDT AMGN Biomed to host a conference Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.